X

Trial Profile

Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Everolimus (Primary) ; Fulvestrant (Primary) ; Neratinib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms GERTRUDE

Most Recent Events

24 Oct 2023 Planned End Date changed from 1 Sep 2031 to 1 Oct 2031.
24 Oct 2023 Planned primary completion date changed from 1 Sep 2030 to 1 Oct 2030.
24 Oct 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com